Global Non-small Cell Lung Cancer Treatment Market, by Type (Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma, and Large Cell Neuroendocrine Tumors), by Treatment (Chemotherapy, Targeted Therapy (Bevacizumab (Avastin), Necitumumab (Portrazza), and Ramucirumab (Cyramza)), and Immunotherapy (Nivolumab (Opdivo), Atezolizumab (Tecentriq), and Others)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was estimated to be valued at US$  19,161.7 million in 2019, and is expected to exhibit a CAGR of 9.3% over the forecast period (2019-2027), as highlighted in a new report published by Coherent Market Insights.

Increasing product launches of biosimilars of Bevacizumab is expected to drive growth of the Non-small cell lung cancer treatment market over the forecast period. For instance, in July 2019, Amgen and Allergan plc collaborated and launched MVASI (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab) in combination with chemotherapy for Non-small cell lung cancer.

Furthermore, in 2018, F. Hoffmann-La Roche AG launched atezolizumab under the brand name Tecentriq for the treatment of Non-small cell lung cancer (NSCLC) in India. Moreover, in 2019 Sandoz, a subsidiary of Novartis AG, launched generic oncology medicine, gefitinib, indicated for adult patients with metastatic non-small cell lung cancer.

Browse 26 Market Data Tables and 33 Figures spread through 175 Pages and in-depth TOC on "Global Non-small Cell Lung Cancer Treatment Market , by Type (Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma, and Large Cell Neuroendocrine Tumors), by Treatment (Chemotherapy, Targeted Therapy (Bevacizumab (Avastin), Necitumumab (Portrazza) and Ramucirumab (Cyramza)), and Immunotherapy (Nivolumab (Opdivo), Atezolizumab (Tecentriq), and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027"

To know the latest trends and insights related to global non-small cell lung cancer treatment market, click the link below:

https://www.coherentmarketinsights.com/market-insight/non-small-cell-lung-cancer-market-241

Major market players are focused on various business strategies such as research and development, in order to enhance their market position. For instance, in March 2019, Eli Lily and Company announced the positive result for its Phase 3 RELAY study of CYRAMZA (ramucirumab), meeting primary endpoint of progression-free survival (PFS) and exhibited impressive improvement in patients that lived without their cancer spreading or growing after treatment. CYRAMZA is indicated for the treatment of Non-small cell lung cancer.

Key Takeaways of the Global Non-small Cell Lung Cancer Treatment Market:

  • The global Non-small cell lung cancer treatment market is expected to exhibit a CAGR of 9.3% over the forecast period (2019-2027), owing to increasing launches of product for non-small cell lung cancer treatment
  • Among type, adenocarcinoma segment is expected to account for a major revenue share by 2027, owing to increasing cases of lung adenocarcinoma. For instance, according to the American Cancer Society (ACS) data of October 2019, lung adenocarcinoma accounts for 40% of all lung cancers cases, globally. It is more prone in women. Furthermore, according to the same source, younger population (aged 20-46), who have lung cancer are more likely to have lung adenocarcinoma than other lung cancers, globally.
  • Major players operating in the global Non-small cell lung cancer treatment market include Pfizer Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Boehringer Ingelheim GMBH, Novartis AG, Bristol-Myers Squibb Company, and Merck & Co., Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner